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ABSTRACT 
Cases of low-grade B-cell lymphoma presenting primarily in the bone marrow are 
rare, and its clinicopathology remains unclear. We retrospectively examined patients 
with low-grade B-cell lymphoma presenting primarily in the bone marrow. Fourteen 
patients met the inclusion criteria, including 5 with lymphoplasmacytic lymphoma 
(LPL), 3 with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 
2 with follicular lymphoma (FL), and 4 with low-grade B-cell lymphoma not otherwise 
specified (LGBCL-NOS). The median age was 69.5 years (range, 42–89 years), and a 
slight male predominance was noted (9 men and 5 women, 1.8: 1). 
Immunohistochemically, all cases were positive for CD20. One case was positive for 
CD138. Both cases of FL were positive for CD10 and B-cell lymphoma 2 (BCL-2), and 
immunoglobulin heavy locus IgH/BCL-2 rearrangement was observed by fluorescence 
in situ hybridization. The myeloid differentiation primary response gene (88) (MYD88) 
L265P mutation was observed in 3 of 5 LPL, 1 of 2 FL, and 2 of 4 LGBCL-NOS 
patients. Paraproteinemia was observed in 10 patients; immunoglobulin M and G 
paraproteinemia were observed in 6 and 3 patients, respectively. In this patient series, 3 
patients had died at a median follow-up of 36.5 months; the cause of death of 1 LPL 
patient was malignant lymphoma itself. Thus, low-grade B-cell lymphoma presenting 
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primarily in the bone marrow has various subtypes, and approximately one-third of the 
patients had LGBCL-NOS. The immunophenotypic features and MYD88 L265P 
mutation data of LGBCL-NOS suggested that some cases present with characteristics 
similar to those of LPL or marginal zone lymphoma. 
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INTRODUCTION 
Low-grade B-cell lymphomas that are localized to certain organs have specific 
characteristics. For example, extranodal marginal zone lymphoma of the 
mucosa-associated lymphoid tissue (MALT) of the stomach is associated with chronic 
inflammation caused by Helicobacter pylori, gastrointestinal follicular lymphoma (FL) 
frequently occurs at the duodenum and spreads to the small intestine, and primary 
cutaneous follicle center lymphoma is localized to the skin and exhibits an indolent 
clinical course. 
Low-grade B-cell lymphomas such as FL, lymphoplasmacytic lymphoma (LPL), 
and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) frequently 
involve the bone marrow [1-5]. However, cases of low-grade B-cell lymphoma 
presenting primarily in the bone marrow are quite rare. Only one report [6] concerning 
primary bone marrow lymphoma has investigated this issue; however, the authors 
included aggressive B-cell lymphomas such as diffuse large B-cell lymphoma in the 
inclusion criteria. Therefore, the clinicopathological features and clinical behavior of 
low-grade B-cell lymphomas presenting primarily in the bone marrow are still unknown. 
In the present study, we retrospectively analyzed a series of 14 patients with low-grade 
B-cell lymphoma presenting primarily in the bone marrow and attempted to clarify the 
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clinicopathological and genotypic characteristics. 
 
 
MATERIALS AND METHODS 
Patient selection 
The pathology database at our institution was searched for cases of low-grade B-cell 
lymphoma involving the bone marrow from January 2000 to December 2011. A total of 
199 patient samples of bone marrow were retrieved. From them, cases of mantle cell 
lymphoma, multiple myeloma, aggressive B-cell lymphoma, or acute B-cell 
lymphoblastic leukemia as well as cases presenting with lymph node swelling, 
splenomegaly, hepatomegaly, any mass detectable by physical examination or computed 
tomography (CT), or bone changes detected by CT were excluded. Furthermore, among 
the patients who underwent 
18
F fluorodeoxyglucose positron emission tomography/CT 
(
18
F-FDG PET)/CT, those who exhibited a high standardized uptake value of 
18
F-FDG 
outside the bone marrow were excluded. All patients in the present study underwent 
thoracic, abdominal, and pelvic CT scanning.  
Diagnoses were made according to the current WHO 2008 classification. In the 
present study, cases of low-grade B-cell lymphoma that did not meet any classification 
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criteria according to the WHO classification were considered as low-grade B-cell 
lymphoma not otherwise specified (LGBCL-NOS). Multiple myeloma was ruled out by 
using the International Myeloma Working Group (IMWG) criteria [7]. CD20-positive 
multiple myeloma was also ruled out based on the presence of certain clinical features 
such as the absence of lytic bone lesions on CT, as well as CD19 positivity [8] and 
cyclin D1 negativity on immunohistochemistry [9]. B lymphoblastic 
leukemia/lymphoma were ruled out based on the findings of histopathology and 
immunostaining of TdT and MIC2. B-cell prolymphocytic leukemia was ruled out 
based on the findings of a peripheral blood smear. Hairy cell leukemia was ruled out 
based on the presence ofAnnexinA1 negativity by immunostaining and CD103 
positivity by flow cytometry. Hairy cell leukemia-variant and splenic B-cell 
lymphoma/leukemia unclassifiable were ruled out based on the findings of flow 
cytometry and presence of splenomegaly.  
A total of 14 patients met the inclusion criteria. Of the 14 patients, bone marrow 
biopsy findings were available in 7 patients and clot section findings were available in 
the other 7 patients. The major differential diagnostic points between CLL/SLL and 
LGBCL-NOS are described as follows. First, clinically, the patients who had elevated 
white blood cell counts generally had CLL/SLL; these cases were excluded for the 
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diagnosis of LGBCL-NOS. Second, histologically, the case that presented with 
monotonous cells with a condensed nucleus and partial presence of paraimmunoblasts 
was included among the CLL/SLL cases. Third, CD5- and CD23-positive cases, 
identified using immunohistochemical study or flow cytometry, were also included 
among the CLL/SLL cases and excluded for the diagnosis of LGBCL-NOS. The 
majority of patients with LPL had IgM paraproteinemia. Histologically, tumor cells in 
LPL are predominantly small lymphocytes admixed with plasma cells and plasmacytoid 
cells. Patients who presented with these clinical manifestations and histological 
characteristics were excluded for the diagnosis of LGBCL-NOS. We used the term 
“LGBCL-NOS” for cases that did not meet any WHO criteria, because they could not 
be further subtyped. Bone marrow aspirate cytology was available in 12 patients. Other 
clinical data were collected, including blood cell counts, serum biochemistry, including 
the levels of lactate dehydrogenase (LDH), soluble interleukin 2 receptor (sIL2-R), and 
M protein type. Survival outcomes were also examined. The invasion pattern of the 
bone marrow was evaluated according to the criteria proposed by Arber et al. [1]. The 
study protocol was approved by the Institutional Review Board of Okayama University, 
Okayama, Japan, and written informed consent was obtained from each patient. All 
study procedures were conducted in accordance with the guidelines of the Declaration 
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of Helsinki. 
 
 
Flow cytometric analysis 
Flow cytometric analysis was performed on 13 samples obtained from either bone 
marrow aspirates or peripheral blood using a single-tube, 2-color method as described 
previously [10]. Monoclonal antibodies against CD3, CD5, CD10, CD19, CD20, CD23, 
CD38, CD45, and Igκ and Igλ light chains were used. The data were acquired on a 
FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed 
using CellQuest software (BD Biosciences, San Jose, CA, USA). 
 
Immunohistochemistry and in situ hybridization 
Immunohistochemical analysis was performed on 10% formalin-fixed, 
paraffin-embedded tissue sections. Automated immunostainers (Ventana Medical 
System, Tucson, AZ, USA; BOND-MAX, Leica Microsystems, Melbourne, Australia) 
[11] were used according to the manufacturers’ instructions. The following primary 
antibodies were used (clone, dilution; source): CD20 (L26, 1:200; Dako Corporation, 
Carpentaria, CA, USA), CD3 (LN10, 1:200; Leica Microsystems), CD5 (4C7, 1:100; 
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Novocastra, Newcastle upon Tyne, UK), CD10 (56C6, 1:100; Novocastra), B-cell 
lymphoma 2 (BCL-2) (3.1, 1:400; Novocastra), CD21 (1F8, 1:20; Dako Corporation), 
CD23 (1B12, 1:100; Novocastra), Cyclin D1 (SP4, 1:50; Nichirei Biosciences, Tokyo, 
Japan), CD19 (LE-CD19, 1:50; Dako Corporation), CD138 (MI15, 1:100; Dako 
Corporation), B-cell lymphoma 6 (BCL-6) (PG-B6P, 1:100; Dako Corporation), 
multiple myeloma oncogene 1 (MUM1) (MUM1p, 1:50; Dako Corporation), 
AnnexinA1 (rabbit polyclonal to AnnexinA1, 1:100; Abcam, Cambridge, UK), and 
Ki-67 (MIB-1, 1: 10,000; Novocastra). After immunostaining, CD20, CD3, CD5, CD10, 
BCL-2, CD23, Cyclin D1, CD19, CD138, BCL-6, and AnnexinA1 were scored 
quantitatively as negative, partially positive (i.e., <30% positive tumor cells), or positive 
(i.e., >30% positive tumor cells). Cells were considered MUM1 positive if they 
exhibited >30% positivity for MUM1. Furthermore, the Ki-67 index was determined; it 
was considered low and high at <10% and >10%, respectively. Fluorescence in situ 
hybridization (FISH) analysis for immunoglobulin heavy locus (IgH)/BCL-2 
rearrangement t(14;18) was performed using a commercially available FISH probe set 
(Abbott Molecular Inc., Wiesbaden, Germany) [12] on paraffin blocks available from 
patients #9–14. FISH analysis for API2/MALT1 t(11; 18)(q21; q21) was also performed 
for LPL and LGBCL-NOS patients using a commercially available FISH probe set 
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(Abbott Molecular Inc., Des Plaines, IL, USA) [13]. FISH analysis for IRF4 gene 
translocation was also performed for immunohistochemically MUM1-positive samples 
using a commercially available FISH probe set (KREATECH, Amsterdam, The 
Netherlands) [14]. 
 
Screening for the myeloid differentiation primary response gene (88) (MYD88) 
L265P mutations 
DNA was isolated from formalin-fixed paraffin-embedded tissue using the QIAmp 
system (Qiagen). MYD88 genes were amplified by polymerase chain reaction (PCR). 
The forward and reverse primers were used for MYD88 were 
5′-GTTGAAGACTGGGCTTGTCC-3′ and 5′-GTGCAGGGGTTGGTGTAGTC-3′, 
respectively. The purified PCR products were directly sequenced in both directions 
using the BigDye Terminator Cycle Sequencing Kit and analyzed on an automatic 3500 
DNA sequencer (Applied Biosystems). 
 
IgVH sequence analysis 
Immunoglobulin heavy chain gene rearrangement was detected by PCR. DNA was 
extracted from formalin-fixed paraffin-embedded tissue sections. Immunoglobulin 
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heavy chain genes were amplified by using semi-nested PCR, with the primers directed 
to the framework 2 region (FR2A: 5′-TGGRTCCGMCAGSCYYCNGG-3′ for both the 
first and second PCR) and the joining region (LJH: 5′-TGAGGAGACGGTGACC-3′ for 
the first PCR, and VLJH: 5′-GTGACCAGGGTNCCTTGGCCCCAG-3′ for the second 
PCR). DNA samples were separately subjected to PCR with TAKARA Ex Taq (Takara 
Bio Inc., Otsu, Japan). The amplified products were electrophoresed on a 3% agarose 
gel. A product was determined to be “clonal” if a single or dominant discrete band was 
apparent. To sequence clonal bands, the PCR products were purified with ExoSAP-IT 
(USB, Affymetrix). Sequencing was performed using the BigDye Terminator version 
3.1 Cycle Sequencing Kit (AB, Warrington, UK), and the reaction products were 
analyzed on an automatic 3130xl DNA sequencer (Applied Biosystems). The nucleotide 
sequences of VH regions were compared to deposited sequences using the IgBLAST 
database (http://www.ncbi.nlm.nih.gov/igblast/) in the PubMed Center. 
 
 
RESULTS 
Clinical manifestations and outcomes 
The patients’ clinical characteristics are summarized in Table 1. The median age was 
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69.5 years (range, 42–89 years), and a slight male predominance was noted (9 men and 
5 women, 1.8:1). Compared to that noted among other subtypes, a female predominance 
(1 man and 3 women, 1:3) was observed in LGBCL-NOS. Four patients had tumor cells 
in the peripheral blood (#6, 9, 11, and 13), 3 patients presented with leukopenia (white 
blood cell [WBC] count < 4.0 × 10
9
/L), 7 patients presented with anemia (hemoglobin 
[Hb] concentration < 10.0 g/dL), and 5 patients presented with thrombocytopenia 
(platelets [Plt] < 15 × 10
9
/L). Four patients showed elevated LDH levels, and 6 patients 
showed high sIL2-R levels (sIL2-R > 2.0 × 10
3
U/mL). With regard to M protein 
subtypes, all 5 LPL patients and 1 CLL/SLL patient had IgM, whereas 1 FL and 2 
LGBCL-NOS patients had IgG. 
Chemotherapy was performed in 9 of 14 patients. Among them, 7 patients received 
rituximab-containing therapy. 
Three patients (#1, 2, and 8) died after 71, 83, and 62 months, respectively, with a 
median follow-up time of 36.5 months (range, 5–90 months): 2 patients had LPL (#1 
and 2) and the other patient had CLL/SLL (#8). One LPL patient (#1) died because of 
intestinal hemorrhage, which was probably caused by thrombocytopenia. The other LPL 
patient (#2) died because of primary disease. One CLL/SLL patient (#8) died because of 
cerebral infarction. 
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Pathological findings and FISH results 
Among 14 patients with low-grade B-cell lymphoma localized to the bone marrow, 
5, 3, 2, and 4 patients had LPL, CLL/SLL, FL, and LGBCL-NOS, respectively. The 
histologic and immunophenotypic features are summarized in Table 2, Figure 1, and 
Figure 2. 
In LPL patients, the tumor cells exhibited diffuse proliferation and included small- 
to medium-sized lymphocytes, plasmacytoid lymphocytes, and plasma cells (Figure 2A). 
The bone marrow invasion pattern was evaluated in 3 patients, which included mixed 
paratrabecular and interstitial, mixed nodular and interstitial, and interstitial patterns, 
respectively. With regard to immunohistochemistry, 5 samples were CD20 positive, 
CD19 positive, and CD138 negative, whereas 1 was CD5 positive. In CLL/SLL samples, 
the tumor cells consisted mainly of small monotonous lymphocytes with round nuclear 
contours; in addition, paraimmunoblast clusters were observed (Figure 2F). 
Immunohistochemical analysis revealed that all 3 were CD20 positive. In addition, all 
samples were positive for CD5 and CD23, as determined by flow cytometric analysis 
and/or immunohistochemical analysis. In 2 FL patients, tumor cells showed a diffuse or 
mixed nodular and interstitial pattern of invasion, and tumor follicles were not observed 
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in either specimen. Tumor cells consisted of centrocytic cells admixed with some 
centroblastic cells (Figure 2K). Both samples were CD20, CD10 (#10 was partial), and 
BCL-2 positive according to immunohistochemical analysis. Follicular dendritic cells 
were not detected by CD21 immunostaining. The FISH study demonstrated IGH-BCL2 
translocations. 
As a consequence of the exclusion criteria, 4 patients were classified as 
LGBCL-NOS. No patients had elevated WBC counts or IgM paraproteinemia. In all 4 
bone marrow specimens, small- to medium-sized monotonous cells with condensed 
nuclear chromatin were observed without plasma cells, plasmacytoid lymphocytes, or 
paraimmunoblast clusters. In 2 patients, the pattern of bone marrow invasion was 
evaluated, which included mixed interstitial and diffuse, and diffuse patterns. 
Immunohistochemical analysis showed that all 4 samples were CD20 positive. One 
patient (#14) was partially positive for CD10 and CD138. This patient’s sample was 
positive for CD19 and negative for Cyclin D1. The samples of 2 of 4 LGBCL-NOS 
patients were positive for CD23.  
There were no IGH-BCL2 translocations in any of the 4 LGBCL-NOS patients 
according to the FISH study. Furthermore, the FISH study showed that there were no 
API2-MALT1 translocations in LPL or LGBCL-NOS patients (data not shown). In 
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addition, there were no IRF4 rearrangements in MUM1-positive patients (#8, #12, and 
#14; data not shown). 
 
MYD88 L265P mutation and IgVH gene usage analysis 
The MYD88 L265P mutation was found in 6 of 14 patients including 3 of 5 LPL, 1 
of 2 FL, and 2 of 4 LGBCL-NOS patients. The MYD88 L265P mutation was not found 
in any of the CLL/SLL patients (Table 2 and Figure 3). VH usage was VH3-23, VH1-3, 
and VH4-34 in 3 CLL/SLL patients; VH3-7 and VH4-34 in 2 FL patients; and VH3-66 
and VH4-59 in 2 LGBCL-NOS patients. 
 
 
DISCUSSION 
The present study analyzed different subtypes of low-grade B-cell lymphoma 
localized to the bone marrow, including LPL, CLL/SLL, FL, and LGBCL-NOS. 
Torlakovic et al. [15] reported that paratrabecular and mixed paratrabecular patterns are 
common in FL. Moreover, interstitial and mixed interstitial patterns are common in LPL 
[1]. However, bone marrow invasion patterns vary in the other types of low-grade B-cell 
lymphomas [1]. In the present study, paratrabecular, nodular, interstitial, and diffuse 
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patterns were all observed. However, the cases of low-grade B-cell lymphoma did not 
exhibit any specific pattern. Moreover, none of the samples exhibited an intra-sinusoidal 
pattern. 
FL generally occurs in the lymph nodes and rarely in the gastrointestinal tract. After 
excluding other sites of involvement, only 2 patients met the diagnostic criteria for FL. 
Martinez et al. [6] described a series of 19 patients with primary bone marrow B-cell 
lymphoma, and only 4 patients had FL, including 3 patients who were positive for 
CD10 and BCL2. The findings of their patient series corroborate the present results 
regarding the rarity of primary bone marrow FL. Histologically, FL samples did not 
exhibit any tumor follicles. Only 4.6% of nodal FL cases exhibit a follicular pattern in 
the bone marrow [15]. Therefore, the 2 specimens in the present study might be the 
diffuse type of FL. 
The tumor cells of patient #6 weakly expressed BCL6. Moreover, BCL6 was 
overexpressed in the tumor cells of patient #8. BCL6 is certainly a germinal center 
marker and is expressed in B-cell lymphoma of germinal center origin (i.e., FL, 
Burkitt’s lymphoma, and some diffuse large B-cell lymphoma). CLL cells rarely express 
different levels of BCL6 regardless of mutational status, or the number of mutations or 
polymorphisms [16]. The CLL patients in the present study exhibited a high frequency 
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of BCL6 expression. However, only a few CLL/SLL patients were included in the case 
series, and hence, the high frequency of BCL6 expression may have been accidentally 
detected. Thus, further studies are required to completely understand these phenomena. 
MYD88 is an adaptor molecule in Toll-like receptor and interleukin-1 receptor 
(IL-1R) signaling that leads to NF-κβ activation. Whole-genome sequencing in 
Waldenström macroglobulinemia identified a somatic variant (T→C) at position 
38,182,641 in chromosome 3p22.2 that causes an amino acid change from leucine to 
proline (L265P) in the MYD88 protein [17]. The MYD88 L265P mutation is found in 
67–100% of LPL cases [17-22]. Moreover, the MYD88 L265P mutation is occasionally 
found in non-germinal center diffuse large B-cell lymphoma (19%), but is rare or absent 
in germinal center diffuse large B-cell lymphoma (0%) [21]. Moreover, the MYD88 
L265P mutation is rarely found in MALT lymphoma (9%) [17, 18, 22], CLL/SLL 
(0–3%) [19, 20, 22], FL (4%) [20], or splenic marginal-zone lymphoma (4–21%) [17-19, 
22].  
In the present study, the MYD88 L265P mutation was found in 3 of 5 LPL patients, 1 
of 2 FL patients, and 2 of 4 LGBCL-NOS patients. Thus, the present results suggest that 
some LGBCL-NOS cases may share characteristics with LPL or marginal zone B-cell 
lymphoma. Nevertheless, it remains unclear whether LGBCL-NOS patients with the 
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MYD88 L265P mutation should be diagnosed with LPL. Therefore, further study is 
required to resolve this issue. However, patients with IgM paraproteinemia and LPL 
histology may be distinguished from those with LGBCL-NOS.  
Among all patients analyzed, 3 died. One patient died of malignant lymphoma, whereas 
another patient died of intestinal hemorrhage, which was probably caused by severe 
thrombocytopenia. Thus, the cause of death was not only malignant lymphoma but also 
involved cytopenia or therapy. Therefore, the prognosis of low-grade B-cell lymphoma 
localized to the bone marrow should be studied further. 
In conclusion, several subtypes of primary bone marrow lymphoma were identified 
in primary bone marrow lymphoma. Approximately one-third of patients with primary 
bone marrow lymphoma were classified as LGBCL-NOS, and shared 
clinicopathological and genotypic characteristics with LPL or marginal zone B-cell 
lymphoma. As the present study involved a relatively small sample size, additional 
studies with larger sample sizes are required to clarify the pathophysiology and 
prognosis of this disease. 
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FIGURE LEGENDS 
 
FIGURE 1. Histology of (A) LPL (#2), (B) CLL/SLL (#8), (C) FL (#10), and (D) 
LGBCL-NOS (#13) (hematoxylin and eosin [H&E], ×4). (A) LPL (#2) exhibits an 
interstitial pattern. (B) CLL/SLL (#8) exhibits aggregates of small lymphoid cells. (C) 
FL (#10) exhibits nodular (center) and interstitial (left) patterns. (D) LGBCL-NOS 
(#13) exhibits diffuse and interstitial patterns. 
 
FIGURE 2. (A) In LPL (#2), the tumor cells exhibited diffuse proliferation and 
included small- to medium-sized lymphocytes, plasmacytoid lymphocytes, and plasma 
cells. Neoplastic cells in LPL are positive for (B) CD20, but negative for (C) CD10, (D) 
CD5, and (E) Cyclin D1. (F) In CLL/SLL samples (#6), the tumor cells consisted 
mainly of small monotonous lymphocytes with round nuclear contours; in addition, 
paraimmunoblast clusters were observed. Neoplastic cells in CLL/SLL lymphocytic 
lymphoma (CLL/SLL) (#8) are positive for (G) CD20, (H) CD5, and (I) CD23, but 
negative for (J) Cyclin D1. (K) In FL samples (#10), tumor cells consisted of 
centrocytic cells admixed with some centroblastic cells. Neoplastic cells in FL are 
positive for (L) CD20, (M) CD10, and (N) BCL-2, but negative for (O) CyclinD1. (P) 
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In LGBCL-NOS (#13), small- to medium-sized monotonous cells with condensed 
nuclear chromatin were observed without plasma cells, plasmacytoid lymphocytes, or 
paraimmunoblast clusters. Neoplastic cells in LGBCL-NOS are positive for (Q) CD20, 
but negative for (R) CD5, (S) CD10, and (T) CyclinD1. 
 
FIGURE 3. The right sequence data shows a MYD88 L265P mutation-positive patient 
sample (A: #2, B: #11). The black arrow shows the mutation site. 
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Table 1. Clinical features and outcomes of low-grade B-cell lymphoma cases restricted to the bone marrow 
No. 
# 
 
Diagnosis 
 
Age 
 
Sex 
 
PS 
WBC 
Count   
(×10
9
/L) 
Hb 
(g/dL
) 
Platelets 
(×10
10
/L) 
sIL2-R 
(U/mL) 
 
M protein 
 
Genetic features 
 
Treatment 
 
Outcome 
 
Cause of 
death 
Follow-up 
time 
1 LPL 
67 M 0 3.3 5.6 15.0 1970 IgMκ 
 
Cyclosporine A Dead 
Intestinal 
hemorrhage 
71 
2 LPL 
73 M 0 3.3 9.8 13.0 420 IgMκ 
 
R-CHOP  Dead lymphoma 83 
3 LPL 
73 M 0 4.9 13.1 40.1 760 
IgMκ, 
BJκ 
 
NO Alive  39 
4 LPL 
76 F 1 4.8 12.6 27.8 540 IgMλ 
46, XX (20/20) Cyclosporine A + 
prednisolone , Rituximab 
Alive  34 
5 LPL 
67 M 1 4.5 13.2 20.9 272 IgMκ 
45, X, -Y (3/20), 47, XY, +18 
(1/20), 46, XY (16/20) 
IAPP  Alive  18 
6 CLL/SLL 
82 F 0 27.8 11.0 16.1 1390 ― 
 
NO 
Lost to 
follow-up 
 88 
7 CLL/SLL 
89 M 4 4.5 11.1 21.0 7950 
subtype 
unclear 
46, XY (number data was not 
obtained) 
NO 
Lost to 
follow-up 
 5 
8 CLL/SLL 
64 M 0 6.8 7.7 46.7 1502 IgMκ 
45, X, -Y (5/20), 47, XY, +Y 
(1/20), 46, XY (14/20) 
Rituximab, Fludarabine Dead 
Cerebral 
infarction 
62 
9 FL 
62 M 0 8.5 6.0 11.9 2090 
IgGκ, 
BJκ 
46, XY, inv(9)(p12q13) (4/4) 
R-CHOP  Alive  90 
10 FL 72 M 0 7.0 7.3 6.5 8569 ― * NO Alive  10 
11 LGBCL-NOS 65 M 0 21.9 13.8 21.0 12700 ― 46, XY (20/20) Cyclophosphamide Alive  55 
12 LGBCL-NOS 80 F 0 6.0 9.5 5.0 4830 ― 46, XX (20/20) R-THP-COP  Alive  32 
13 LGBCL-NOS 42 F 0 2.8 8.3 10.0 5600 IgGκ  Rituximab + Cladribine Alive  18 
14 LGBCL-NOS 47 F 0 5.9 10.7 40.2 2513 IgGκ 46, XX (20/20) NO Alive  22 
CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; F, failure; FL, follicular lymphoma; Hb, hemoglobin; IAPP, ifosfamide + adriamycin + cisplatin + peplomycin; LDH, lactate dehydrogenase; LGBCL-NOS, low-grade B-cell lymphoma not 
otherwise specified; LPL, lymphoplasmacytic lymphoma; PR, partial response; PS, performance status; sIL2-R, soluble interleukin-2 receptor; WBC, white blood cell., R-CHOP (rituximab+cyclophosphamide+ doxorubicin+vincristine+prednisolone), IAPP 
(ifosphamide+adriamycin+cisplatin+peplomycin), Rituximab, R-THP-COP (rituximab, cyclophosphamide, pirarubicin, vincristine and prednisolone), * 47, XY, add(1)(q21), ;t(14;18)(q32:q21), +ider(18)(q10)t(14;18) (3/20), 46, XY (17/20) 
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Table 2. Pathologic and immunophenotypic features of primary low-grade B-cell lymphoma patients 
 
 
No.# 
 
 
Diagnosis 
 
 
Pattern 
 
 
Cellularity 
 
 
CD20 
 
 
CD3 
 
 
CD5 
 
 
CD10 
 
 
BCL2 
 
 
CD23 
 
 
CyclinD1 
 
 
CD19 
 
 
CD138 
 
 
BCL-6 
 
 
MUM1 
 
 
AnnexinA1 
 
Ki-67 
index 
 
FISH 
t(14; 18) 
MYD88 
L265P 
mutation 
1 LPL PT, INT 10% + ― ― ― ND ― ― + ― ― ― ― low ND + 
2 LPL NOD, INT 85% + ― ― ― ND ― ― + ― ― ― ― low ND + 
3 LPL ND 50% + ― ― ― ND ― ― p+ ― ― ― ― low ND ― 
4 LPL ND 10% + ― ― ― ND ― ― p+ ― ― ― ― low ND + 
5 LPL INT 50% + ― + ― ND ― ― p+ ― ― ― ― low ND ― 
6 CLL/SLL ND 85% + ― + ― ND + ― + ― + ― ― low ND ― 
7 CLL/SLL ND 80% + ― ―* ― ND + ― + ― ― ― ― low ND ― 
8 CLL/SLL ND 60% + ― + ― ND + ― + ― + + ― low ND ― 
9 FL DIFF 100% + ― ― + + ― ― + ― ― ― ― low + + 
10 FL NOD, INT 70% + ― ― + + ― ― + ― + ― ― low + ― 
11 LGBCL-NOS ND 100% + ― ― ― ND p+ ― + ― ― ― ― low UD + 
12 LGBCL-NOS ND 80% + ― ― ― ND ― ― + ― ― + ― low ― ― 
13 LGBCL-NOS INT, DIFF 90% + ― ― ― ND ― ― UD ― ― ― ― low UD ― 
14 LGBCL-NOS DIFF 100% + ― ― p+ + + ― + p+ ― + ― low ― + 
*positive based on flow cytometric analysis. 
CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DIFF, diffuse; FL, follicular lymphoma; INT, interstitial; LGBCL-NOS, low-grade B-cell lymphoma not 
otherwise specified; LPL, lymphoplasmacytic lymphoma; ND, not done; NOD, nodular; p+, partially positive; PT, paratrabecular; UD, undetermined 
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